TY  - JOUR

T1  - Modelling the cost effectiveness of interferon beta and glatiramer acetate in the management of multiple sclerosis. Commentary: evaluating disease modifying treatments in multiple sclerosis.

JO  - BMJ

PY  - 2003/03/08

AU  - Chilcott J

AU  - McCabe C

AU  - Tappenden P

AU  - O'Hagan A

AU  - Cooper NJ

AU  - Abrams K

AU  - Claxton K

AU  - Miller DH

AU  - Cost Effectiveness of Multiple Sclerosis Therapies Study Group

ED  - 

DO  - DOI: 10.1136/bmj.326.7388.522

VL  - 326

IS  - 7388

SP  - 522

Y2  - 2024/12/22

ER  -